Iva Bužančić

Ms. Iva Bužančić

University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, Zagreb, Grad, Croatia
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
IBIva Bužančić
Iva Bužančić
IKIngrid Kummer
Ingrid Kummer
MDMargita Držaić
Margita Držaić
MHMaja Ortner Hadžiabdić
Maja Ortner Hadžiabdić

1 September 2021 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
IBIva Bužančić
Iva Bužančić
PDPatricia Dragović
Patricia Dragović
TPTajana Iva Pejaković
Tajana Iva Pejaković
LMLuka Markulin
Luka Markulin
MHMaja Ortner Hadžiabdić
Maja Ortner Hadžiabdić
Purpose: To explore how adult patients perceive deprescribing in a country with developing pharmaceutical care. Patients and Methods: This was a multicenter cross-sectional study conducted in ten community pharmacies across Croatia. Community-dwelling adults 40 years and older, taking at least one prescription medication long term, were invited to participate. The revised and validated Patients’ Attitude Towards Deprescribing Questionnaire was used to investigate community-dwelling adults’ opinions on potential medication discontinuation. Questions regarding the patients’ perception of pharmacist competences and involvement as well as patients’ preferences in deprescribing were added. Collected data were analyzed using IBM SPSS Statistics using descriptive and inferential statistical analysis. Binary logistic regression was used to explore potential predictive factors of willingness to have medication deprescribed. All tests were performed as two-tailed and a p < 0.05 was considered statistically significant. Results: A total of 315 adults aged 40 years and older completed the questionnaire. Majority of participants, 83.81% (95% CI, 79.72% to 87.90%) stated that they were satisfied with their medications, and 83.81% (95% CI, 79.72% to 87.90%) would be willing to deprescribe one or more medications. Participants expressed a positive attitude toward pharmacists’ competences (68.89%, 95% CI, 63.75% to 74.03%) and involvement in deprescribing (71.11%, 95% CI, 66.08% to 76.14%). Participants who stated specific medication as deprescribing preference were more likely show dissatisfaction with current medication and show greater willingness to have medication deprescribed. Three factors were found to be associated with a positive attitude towards deprescribing: low concerns about stopping factor score (aOR 0.54, 95% CU=0.35– 0.84; p=0.006), low appropriateness factor score (aOR 0.62, 95% CI=0.39– 0.98; p=0.039), and a positive opinion on pharmacist involvement (aOR 2.35, 95% CI=1.18– 4.70; p= 0.016). Conclusion: This study showed the patient’s willingness for deprescription as well as their positive attitude towards pharmacists being involved in the process. Results favour transition to a patient-centred care and shared-decision making model.

1 July 2022 in Pharmacy
Verified
Journal Article
Open access
PDF file
IBIva Bužančić
Iva Bužančić
MHMaja Ortner Hadžiabdić
Maja Ortner Hadžiabdić
Successful implementation of deprescribing requires exploring healthcare professionals’ opinions, preferences, and attitudes towards deprescribing. The aim of this study was to develop and validate the questionnaire exploring healthcare providers’ opinions preferences and attitudes towards deprescribing (CHOPPED questionnaire). This was a cross-sectional on-line survey. A comprehensive 58-item questionnaire, in two versions (for pharmacists and physicians), was developed through an extensive literature review and interviews with experts. The questionnaire was validated, and its reliability was assessed through data collected from 356 pharmacists and 109 physicians. Exploratory factor analysis was performed, and 37- and 35-item questionnaires were developed. Ten factors were identified: knowledge, awareness, patient barriers and facilitators, competencies barriers and facilitators, collaboration barriers and facilitators, and healthcare system barriers and facilitators. The CHOPPED tool has satisfactory face, content (CVR > 0.62) (content validity ratio), construct, and criterion validity. The reliability statistics of all factors in both versions was acceptable with Cronbach’s alpha > 0.6. Test–retest reliability analysis showed that gamma rank correlations of total factor scores were strong and very strong (between 0.519 and 0.938). The CHOPPED tool can be used as a valid and reliable tool to explore healthcare providers’ opinions and attitudes toward discontinuing medications in the primary care setting in Croatia.

23 September 2022 in Pharmacy
Verified
Journal Article
Open access
PDF file
IBIva Bužančić
Iva Bužančić
TPTajana Iva Pejaković
Tajana Iva Pejaković
MHMaja Ortner Hadžiabdić
Maja Ortner Hadžiabdić
The COVID-19 pandemic has had a negative impact on patients’ mental health. The aim of this study was to explore whether the pandemic influenced the use and prescription of benzodiazepines and increased the need for community pharmacist involvement in counselling on deprescribing. Electronic prescription-related data from one pharmacy in Croatia were retrospectively collected for the COVID-19 period (April 2020 to March 2021) and compared with pre-COVID-19 (April 2019 to March 2020) data. Data were collected for patients diagnosed with anxiety disorders who filled out more than one prescription for benzodiazepines, and included age, sex, number of medicines, benzodiazepines, and comorbidities. A total of 1290 benzodiazepine users were identified; of these, 32.87% started using benzodiazepines during the COVID-19 period, while 35.2% continued with benzodiazepine use. More than half of all benzodiazepine users were identified as potential deprescribing candidates (dispensed more than three prescriptions). Women, older patients, multimorbid individuals, and patients with polypharmacy were more likely to use benzodiazepines for a prolonged period. The results show a negative trend of benzodiazepine usage among community-dwelling patients during the pandemic. Community pharmacists can identify potential candidates for deprescribing and initiate a process that ensures more rational use of benzodiazepines and increases the safety of treatment.

22 May 2023 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
IBIva Bužančić
Iva Bužančić
MHMaja Ortner Hadžiabdić
Maja Ortner Hadžiabdić

14 March 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
IBIva Bužančić
Iva Bužančić
MDMargita Držaić
Margita Držaić
IKIngrid Kummer
Ingrid Kummer
MHMaja Ortner Hadžiabdić
Maja Ortner Hadžiabdić
JBJovana Brkić
Jovana Brkić
DFDaniela Fialová
Daniela Fialová
Pharmacist’s geriatric assessment can provide valuable insights into potential deprescribing targets, while including important information on various health-related domains. Data collected from a geriatric assessment questionnaire, for 388 patients, from the Croatian cohort of the EuroAgeism H2020 ESR 7 international project, along with guideline-based deprescribing criteria, were used to analyse potentially inappropriate prescribing of four medication groups (benzodiazepines (BZN), proton pump inhibitors (PPI), opioids, and non-steroidal anti-inflammatory drugs (NSAID)), and to assess the deprescribing potential. Binary logistic regression was used to explore the effects of age, gender, number of medicines and diagnoses, self-reported health, frailty score, and healthcare utilization on the likelihood of needing deprescribing. More than half of participants (n = 216, 55.2%) are candidates for deprescribing, with 31.1% of PPI, 74.8% of NSAID, 75% of opioid, and 96.1% of BZN users meeting at least one criterion. Most common criteria for deprescribing were inappropriately long use and safety concerns. Women (aOR = 2.58; p < 0.001), those reporting poor self-reported health (aOR = 5.14; p < 0.001), and those exposed to polypharmacy (aOR = 1.29; p < 0.001) had higher odds of needing to have medicines deprescribed. The high rate of deprescribing potential warrants prompt action to increase patient safety and decrease polypharmacy. Pharmacist’s geriatric assessment and deprescribing-focused medication review could be used to lead a personalised approach.